Weight gain in perimenopause does not behave like the weight gain of earlier decades. It settles at the waist, it resists the methods that used to work, and it arrives alongside broken sleep and slower recovery. That pattern is real. Whether a GLP-1 medication is the right answer to it is a more specific question than the marketing suggests — here is what these drugs do, what they do not do, and the questions that separate a responsible program from a subscription.
Where we stand: Menova is an independent publication. We sell no medication and prescribe nothing. We do earn referral commissions from some care providers we compare, disclosed on our affiliate disclosure page, and it never changes what we say about them. This is general education, not medical advice.
What is actually changing in midlife
Before considering any medication, it helps to know what you are treating:
- Fat redistributes to the abdomen as estrogen falls — often a change in shape more than in weight; see menopause belly fat.
- Muscle mass declines with age unless defended, and muscle is where most glucose is disposed of.
- Insulin sensitivity worsens around the transition, independently of weight; see insulin resistance in menopause.
- Sleep loss raises appetite and reduces next-day movement.
Notably, large studies of energy expenditure across the lifespan find metabolic rate is relatively stable through midlife. The change is mostly composition, insulin handling, and sleep — which is why the interventions that work are specific rather than "eat less."
What GLP-1 medications do
GLP-1 is a hormone the gut releases after eating. These medications mimic that signal: they slow stomach emptying, increase satiety, improve blood sugar regulation, and reduce what many people describe as food noise — the constant background negotiation about eating.
They are effective. In trials, average weight loss is substantial, and there are meaningful cardiometabolic benefits beyond weight for some populations. That effectiveness is not in dispute.
What they are not
Three honest limits:
- They are not a menopause treatment. They do nothing for hot flashes, sleep, mood, or vaginal symptoms, and they are not a substitute for a conversation about hormone therapy if those are your problems.
- They are not short-term. Trials consistently show weight returns after stopping. Framing them as a course you complete is misleading; they are closer to blood pressure medication in that respect.
- They do not protect muscle. Rapid weight loss takes lean mass along with fat, and midlife already erodes muscle. This is the single most under-discussed issue for women in this age group.
The muscle point, in more detail
If you take one thing from this article, take this. A significant proportion of the weight lost on these medications can be lean tissue, and losing muscle in your fifties worsens the exact metabolic problem you are trying to solve — as well as bone, balance, and long-term independence.
Which means resistance training and adequate protein matter more on these drugs, not less:
- Two resistance sessions a week, non-negotiable — see strength training in menopause
- Protein at every meal, which is harder when appetite is suppressed and needs deliberate planning; see eating for menopause
- Ask how muscle will be monitored, not just weight
A program that prescribes without raising this is not looking after you.
Side effects and safety
Common: nausea, vomiting, diarrhea or constipation, reflux, and fatigue, mostly during dose escalation. Slower titration usually helps.
Less common but serious: pancreatitis, gallbladder disease, and, with rapid weight loss, a raised risk of gallstones. These medications carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. They should be discussed carefully if you have a history of pancreatitis, gastroparesis, or significant gastrointestinal disease.
Also worth knowing: they slow gastric emptying, which is relevant before surgery or procedures requiring sedation — tell any anesthetist. And they can affect the absorption of oral medications, including oral contraceptives in some cases.
Questions that separate a good program from a bad one
Bring these to any provider:
- What is my baseline picture — HbA1c, fasting glucose, lipids, blood pressure, thyroid?
- What are realistic expectations at three, six, and twelve months?
- Which side effects mean we pause or stop?
- How will we protect and monitor muscle mass, not just weight?
- What is the plan if I stop — tapering, maintenance, or nothing?
- Is this FDA-approved medication or a compounded version, and why?
- What does the total cost look like over a year, including dose escalation?
A responsible program asks about your history, medications, and goals before prescribing anything, and is willing to say no.
The compounded question
Compounded semaglutide and tirzepatide have been widely sold, often at lower prices, and the regulatory situation around them has shifted as manufacturer shortages resolved.
Where this stands, with dates. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage in February 2025, and the grace period that had allowed widespread compounding ended in May 2025. In April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may compound from, having found no clinical need — a proposal, not yet a final rule, with comments taken through June 2026. Narrow exceptions remain for a documented clinical need for an individual patient.
That matters when you are looking at a price. A compounded GLP-1 advertised at a fraction of the approved product is operating in a lane the regulator has been closing, which is a different proposition from a discount.
Compounded versions are not FDA-approved products and are not evaluated for safety, effectiveness, or quality in the same way. If a program offers one, ask directly why, what is in it, and where it is made — the same scrutiny we apply to compounded hormones in compounded versus FDA-approved HRT.
What to do first, whatever you decide
These are worth doing regardless, and for some women they are enough:
- Resistance training twice a week — the highest-value habit in midlife
- Protein at every meal, especially breakfast
- Fix sleep, because appetite regulation on five broken hours is a losing fight; see perimenopause sleep problems
- Walk after meals, which measurably blunts glucose rises
- Reconsider alcohol — calories, worse sleep, less next-day movement; see alcohol in midlife
- Rule out the other causes of midlife fatigue and weight change — thyroid, iron, sleep apnea; see when menopause might not be the answer
Where hormone therapy fits
Hormone therapy is not a weight treatment and should never be sold as one. But if hot flashes and night sweats are wrecking your sleep, treating them removes a large obstacle to everything above — and there is evidence it modestly reduces abdominal fat accumulation. See does HRT cause weight gain and midlife weight and energy changes.
Comparing programs
If you decide to explore this route, the programs differ on clinician access, whether they use FDA-approved or compounded medication, monitoring, and total cost. Our GLP-1 program comparison lays those out side by side, and semaglutide versus tirzepatide covers the medication choice itself. Our guide to getting a GLP-1 online covers the process.
The free 2-minute Menova self-check helps you separate what is menopausal from what is metabolic before you start — no account, not a diagnosis, and your answers never leave your device.
This article is general education, not medical advice, and not a recommendation for or against any medication. GLP-1 medications are prescription drugs with significant contraindications and side effects. Decide with a licensed clinician who knows your full history.
Sources: FDA — Semaglutide Medications, NIDDK — Weight Management, The Menopause Society, and ACOG.